

Date: February 13, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”).

Ref: Issue and allotment of 11,70,000 convertible equity warrants by way of preferential issue on private placement basis by Senores Pharmaceuticals Limited (the “Company”) in terms of Chapter V of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 as amended (“SEBI ICDR Regulations”).

Dear Sir/Madam,

In terms of Regulation 30 read with Schedule III of the SEBI LODR Regulations, Chapter V of SEBI ICDR Regulations and in continuation to our earlier intimations dated January 09, 2026 regarding the Notice of Extra-Ordinary General Meeting (“EGM”) dated January 07, 2026, we would like to submit certain amendments, clarifications and additional disclosures to Item No. 1 of the explanatory statement annexed to the EGM Notice dated January 07, 2026 (“Explanatory Statement”), as mentioned herein:

1. On page no. 16 of the EGM Notice, under the ‘Objects of the Preferential Issue’, the disclosure relating to investment in subsidiaries by way of loan for working capital purposes shall be replaced and read as follows:

As per the earlier disclosure submitted by the Company to the stock exchanges on December 15, 2025, the Company has already acquired 75% of the total equity shares of Apnar Pharma Private Limited (“Apnar”). A portion of the funds being raised through the present issue are earmarked for utilization towards investing in Apnar (by way of granting loan) to fund the working capital requirements of Apnar, in one or more tranches.

All other contents of the EGM Notice together with the explanatory statement thereof, save and except as modified or supplemented by the Clarification, shall remain unchanged.

The Clarification is available on the website of the Company at senorespharma.com/and on the website of the Stock Exchanges at www.nseindia.com and www.bseindia.com.

We request you to kindly take note of the clarification and consider the revised details as final and accurate.

For, Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263